Chidamide and apatinib are therapeutically synergistic in acute myeloid leukemia stem and progenitor cells.

ABSTRACT:

Background

Leukemia stem cells (LSCs) are responsible for the initiation and perpetuation of acute myeloid leukemia (AML), and also represent leukemia relapse reservoirs with limited therapeutic approaches. Thus, additional treatment strategies are medical unmet needs to eliminate LSCs.

Methods

Cell counting kit-8 and Annexin-V-FITC/PI assays were used to examine the interaction of chidamide and apatinib on LSC-like cell lines (CD34⁺CD38^- KG1α and Kasumi-1 cells) and primary CD34⁺ AML cells. AML patient-derived xenografts were established to investigate the in vivo efficacy of the combined regimen. RNA sequencing, Glutamine uptake assay, oxygen consumption assay, and western blotting were employed to explore the molecule mechanism for the cyt

SUBMITTER: Zhao H 

PROVIDER: S-EPMC9112613 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature